TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29484546
Drug: 100-TGF (sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-TGF (sodium fluoride NaF associated with tara gum, 1100 mg/L)
Study: 29484546
Drug: 50-TGF (50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50-TGF (50% NaF associated with tara gum + 50% free NaF, 1100 mg/L)
Study: 29484546
Drug: PC (free
Approvals — FDA: no, EMA: no, PMDA: no
Description: PC (free NaF, 1100 mg/L)
Study: 27596550
Drug: Voglibose 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voglibose 0.2 mg for 3 times per day
Study: 12859464
Drug: Intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal fentanyl (50 microg single dose)
Study: 12859464
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (50 microg single dose)
Study: 8571910
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg Fe/kg of AMI 227
Study: 8571910
Drug: 1.1 mg
Normalized name: menthol 1.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.1 mg Fe/kg of AMI 227
Study: 8571910
Drug: 1.7 mg
Normalized name: pectin 1.7 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.7 mg Fe/kg of AMI 227
Study: 30531232
Drug: 9-week stabilization
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-week stabilization exercise therapy program, 60 mins/week
Study: 25240992
Drug: Natural formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural formulation containing tea catechins
Study: 17922560
Drug: UFT (tegafur-uracil)
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (tegafur-uracil) plus leucovorin given as two daily doses (bid)
Study: 17922560
Drug: UFT (tegafur-uracil)
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (tegafur-uracil) plus leucovorin given as three daily doses (tid)
Study: 10338458
Drug: High-dose transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose transdermal nitroglycerin (NTG) 50 to 100 mg daily for 12 hours
Study: 6994786
Drug: Guanfacine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine (3 mg daily)
Study: 6994786
Drug: Guanethidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanethidine (20 mg daily)
Study: 20723033
Drug: Edoxaban 60
Normalized name: edoxaban 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 60 mg
Study: 25739586
Drug: Insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin glulisine (Glu)
Study: 23932834
Drug: Acetaminophen (10-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (10-15 mg/kg/dose, PO) every 6h as necessary
Study: 8520640
Drug: 4.2 MJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.2 MJ diet daily with exercise
Study: 8520640
Drug: 4.2 MJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.2 MJ diet daily without exercise
Study: 2146047
Drug: Danazol 600
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danazol 600 mg daily for 6 months
Study: 2146047
Drug: Goserelin 3.6
Normalized name: goserelin 3.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin 3.6 mg monthly depot injections for 6 months
Study: 386157
Drug: Methylprednisolone and
Normalized name: methylprednisolone and antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone and cyclophosphamide pretreatment (5 g each)
Study: 31994303
Drug: 270 mg
Normalized name: leucine 270 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 270 mg ferrous sulphate twice a day (total elemental iron dose: 160 mg/day)
Study: 31994303
Drug: 270 mg
Normalized name: leucine 270 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 270 mg ferrous sulphate once a day (total elemental iron dose: 80 mg/day)
Study: 31994303
Drug: 270 mg
Normalized name: leucine 270 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 270 mg ferrous sulphate every other day (total elemental iron dose: 80 mg/every other day)
Study: 23314603
Drug: Olanzapine 10
Normalized name: olanzapine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 10 mg orally daily for 3 days
Study: 23314603
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg orally TID for 3 days
Study: 11566255
Drug: Simvastatin and
Normalized name: simvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin and Niacin (S-N) therapy
Study: 9502662
Drug: Aggressive tocolysis
Normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive tocolysis with intravenous magnesium sulfate
Study: 17472992
Drug: Sitaxsentan 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitaxsentan 100 mg or 300 mg daily
Study: 9615797
Drug: Granulocyte/macrophage colony
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte/macrophage colony stimulating factor (GM-CSF), administered as subcutaneous injections for 7 consecutive days to 14 patients.
Study: 9615797
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered as subcutaneous injections for 7 consecutive days to 15 patients.
Study: 31533292
Drug: Qigong exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qigong exercise session (video demonstration via website), delivered twice a day for 12 consecutive weeks
Study: 26083769
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of sodium diclofenac (50mg) once a day for 3 weeks.
Study: 11386413
Drug: High-dose (HD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (HD) chemotherapy
Study: 11386413
Drug: Standard-dose (SD)
Normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose (SD) chemotherapy
Study: 8002509
Drug: Glucose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose infusion (0.5 g/min) after placebo (Pl)
Study: 3201128
Drug: FF5005 (pectin-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF5005 (pectin-containing formulation)
Study: 19721848
Drug: Acute tryptophan
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute tryptophan depletion (ATD) in women with bulimia using serotonin reuptake inhibitors
Study: 19721848
Drug: Acute tryptophan
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute tryptophan depletion (ATD) in bulimic women not using medications
Study: 17192328
Drug: orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: orlistat 120 mg t.i.d.
Study: 15339330
Drug: Infliximab treatment
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab treatment (administered intravenously three times)
Study: 15339330
Drug: Infliximab treatment
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab treatment (once)
Study: 15381516
Drug: Manipulative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manipulative therapy
Study: 9704239
Drug: Diet treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet treatment in Northern California (NoCal)
Study: 9704239
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment in Northern California (NoCal)
Study: 9704239
Drug: Diet treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet treatment in New England (NewEng)
Study: 9704239
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment in New England (NewEng)
Study: 8032580
Drug: Cadralazine 10
Normalized name: cadralazine
DrugBank: Cadralazine (DB13452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadralazine 10 mg once daily
Study: 7000296
Drug: Chlorthalidone 25
Normalized name: chlorthalidone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 25 mg once daily
Study: 2681087
Drug: Parenteral prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral prophylaxis with cefazolin 1 g every 6 hours for 24 hours (2 g for knee-replacement)
Study: 2681087
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of bone cement impregnated with antibiotics (e.g. Palacos-Gentamycin-cement)
Study: 2681087
Drug: Antibiotic selection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic selection adjusted based on ongoing monitoring of antimicrobial resistance
Study: 30374683
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg CBD twice daily
Study: 30374683
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg CBD twice daily
Study: 30374683
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg CBD single dose
Study: 30374683
Drug: Single ascending
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending doses (1500, 3000, 4500 or 6000 mg CBD)
Study: 30374683
Drug: Multiple dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose (750 or 1500 mg CBD)
Study: 27382815
Drug: Group M:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group M: 15 ml of bupivacaine 0.5% + 1 ml of 50 mg MgSO4
Study: 27382815
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: 15 ml of bupivacaine 0.5% + 1 ml of normal saline
Study: 25699352
Drug: Warm water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm water infusion
Study: 10402814
Drug: Propofol titration
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol titration using BIS maintained at 40 during induction (n = 15)
Study: 10402814
Drug: Bolus infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bolus infusion of propofol 2 mg.kg‐1 (n = 15)
Study: 10402814
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (titration and bolus)
Study: 7538179
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment using imipenem/cilastatin sodium (IPM/CS) with G-CSF
Study: 7538179
Drug: Monotherapy on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy on antibiotic
Study: 7538179
Drug: IPM/CS in
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPM/CS in combination with other antibiotics
Study: 7303774
Drug: Short-term lithium
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term lithium therapy (7 days) in combination with methimazole
Study: 7303774
Drug: Methimazole monotherapy
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole monotherapy
Study: 31615388
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of β‐AB and Ivabradine
Study: 28728604
Drug: CPT (clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT (clinical prediction tool) with matched treatment recommendation
Study: 11213884
Drug: Rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 4 mg once daily
Study: 11213884
Drug: Rosiglitazone 8
Normalized name: rosiglitazone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 8 mg once daily
Study: 7914307
Drug: 500 U/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 U/kg rhEPO subcutaneously twice a week for 3 weeks
Study: 2885878
Drug: Carbamazepine (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (average dose 1240 mg/day, blood levels 10.4 +/- 2.2 micrograms/ml)
Study: 30015503
Drug: Cognitive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive treatment control (n=24, 8 women and 16 men)
Study: 7560400
Drug: Full-mouth disinfection
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-mouth disinfection with removal of all plaque and calculus in two visits within 24 hours, tongue brushed with 1% chlorhexidine gel, mouth rinsed with 0.2% chlorhexidine solution, subgingival chlorhexidine (1%) irrigation performed in all pockets
Study: 24138688
Drug: Combination beclometasone/formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination beclometasone/formoterol hydrofluoroalkane (HFA)‐MDI used as both maintenance and reliever therapy
Study: 24138688
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose of maintenance beclometasone/formoterol HFA‐MDI with salbutamol MDI for relief
Study: 21719783
Drug: Allopurinol 300
Normalized name: allopurinol 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 300 mg/d
Study: 15234403
Drug: Reperfusion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reperfusion therapy for acute STEMI
Study: 11236835
Drug: Concurrent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent treatment for both alcohol and social anxiety problems (n = 49)
Study: 11236835
Drug: Individual cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual cognitive behavioral therapy for alcoholism only (n = 44)
Study: 8317644
Drug: Pethidine 100
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine 100 mg added to 40 ml prilocaine 0.25%
Study: 7841567
Drug: Empiric dosing
Normalized name: aspirin / codeine phosphate Oral Tablet [Empirin with Codeine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric dosing
Study: 18166191
Drug: High-dose B-vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose B-vitamin therapy
Study: 16864642
Drug: Asthma-related events
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asthma-related events (oral steroid use, emergency department visits, hospitalizations)
Study: 14650098
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus GG administered orally in yogurt base (10^9 CFU) for 1 month, 1 or 2 doses per day
Study: 1638713
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg captopril
Study: 6395280
Drug: Cefonicid 1
Normalized name: cefonicid 1 g injectable powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefonicid 1 g intravenously or intramuscularly 1 hr before surgery
Study: 6395280
Drug: Cefoxitin 2
Normalized name: cefoxitin 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin 2 g intravenously or intramuscularly 1 hr before surgery and 2 g every 6 hr for 24 hr
Study: 30200582
Drug: Whey Protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey Protein (WP, 77 g/day protein, 580 kcal/day)
Study: 30200582
Drug: Carbohydrate (CHO,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (CHO, 127 g/day carbohydrate, 580 kcal/day)
Study: 25466429
Drug: Fexofenadine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine (60 mg)
Study: 19639726
Drug: Olopatadine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olopatadine (5 mg)
Study: 20659611
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of phenylephrine at 0.15 microg.kg(‐1).min(‐1) after spinal block
Study: 20659611
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of prophylactic phenylephrine 50 microg after spinal block
Study: 20659611
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of phenylephrine 50 microg in case of hypotension
Study: 17882915
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg pseudoephedrine (PSE) four times daily
Study: 7549843
Drug: Cryopreserved marrow
Normalized name: Sus scrofa bone marrow preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryopreserved marrow cells using a mixture of 5% DMSO, 6% HES, and 4% Albumin in Lactated Ringer solution.
Study: 80525
Drug: Tienilic acid
Normalized name: Tienilic acid
DrugBank: Tienilic acid (DB04831)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tienilic acid (mean dose 210 mg)
Study: 80525
Drug: Cyclopenthiazide (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclopenthiazide (mean dose 0.41 mg)
Study: 29446160
Drug: SPF30 daily
Normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: SPF30 daily skin cream
Study: 24736770
Drug: Medium Load
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium Load (ML: 12.5% BM)
Study: 17600973
Drug: Monthly visit
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly visit schedule preference
Study: 8117177
Drug: Micronized fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized fenofibrate (200 mg daily)
Study: 2455414
Drug: Etretinate +
Normalized name: etretinate
DrugBank: Etretinate (DB00926)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etretinate + PUVA treatment
Study: 2455414
Drug: Etretinate monotherapy
Normalized name: etretinate
DrugBank: Etretinate (DB00926)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etretinate monotherapy
Study: 2455414
Drug: Etretinate treatment
Normalized name: etretinate
DrugBank: Etretinate (DB00926)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etretinate treatment (control side)
Study: 2071980
Drug: Multidrug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidrug therapy (MDT) for paucibacillary leprosy
Study: 2071980
Drug: Dapsone (DDS)
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dapsone (DDS) monotherapy
Study: 40572
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg temazepam with alcohol
Study: 40572
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg temazepam with alcohol
Study: 40572
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg temazepam with alcohol
Study: 23704198
Drug: Copenhagen Physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copenhagen Physical Activity after Cancer Treatment (PACT)
Study: 21339010
Drug: Intra-operative radiation
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-operative radiation therapy (IORT) combined with surgical resection (n=73)
Study: 19013603
Drug: Sildenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (50 mg for 1 week run-in and 100 mg for 3 weeks)
Study: 17804354
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (INT) including antidepressants and/or psychotherapy treatment plus EUC
Study: 12022217
Drug: Intrathecal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal midazolam (2 mg) with 1.5 ml of 5% lignocaine
Study: 12022217
Drug: 1.5 ml
Normalized name: Humulin 70/30 1.5 ML Pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 ml of 5% lignocaine only
Study: 2492235
Drug: Follicle-stimulating hormone
Normalized name: Follicle-stimulating hormone receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follicle-stimulating hormone (FSH) administered at different times during the menstrual cycle
Study: 2492235
Drug: Clomiphene citrate,
Normalized name: ClomiPHENE Citrate, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomiphene citrate, 100 mg/day for days 2 to 6; FSH, 150 units/day for days 1 to 4; human menopausal gonadotropin, 150 units/day from day 5 until hCG administration
Study: 4618908
Drug: Controlled trials
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled trials of treatment for liver disease in children
Study: 31654838
Drug: Alectinib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alectinib 600 mg
Study: 2969740
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg doxazosin
Study: 27717996
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (hydration and analgesics only)
Study: 31886707
Drug: Intravitreal dexamethasone
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal dexamethasone implant
Study: 16113424
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with budesonide and formoterol
Study: 16113424
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with inhaled corticosteroids and long-acting beta-agonists
Study: 16113424
Drug: Inhaled bronchodilators
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled bronchodilators (tiotropium)
Study: 11780699
Drug: Novel chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel chemotherapy and new biologic agents
Study: 9623560
Drug: Pulse calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulse calcitriol (3.0 microg twice a week)
Study: 9623560
Drug: Daily calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily calcitriol (0.75 microg a day)
Study: 9623560
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (pulse and daily calcitriol)
Study: 7843579
Drug: Triazolam (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.125 mg, with option to increase to 0.25 mg)